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Abstract
In this article, we compare two strategies for atherosclerosis treatment: drugs and healthy lifestyle. Statins are the principal 
drugs used for the treatment of atherosclerosis. Several secondary prevention studies have demonstrated that statins can sig-
nificantly reduce cardiovascular events including coronary death, the need for surgical revascularization, stroke, total mortality, 
as well as fatal and non-fatal myocardial infarction. These results were observed in both men and women, the elderly, smokers 
and non-smokers, diabetics and hypertensives. Primary prevention studies yielded similar results, although total mortality was 
not affected. Statins also induce atheroma regression and do not cause cancer. However, many unresolved issues remain, 
such as partial risk reduction, costs, several potential side effects, and long-term use by young patients. Statins act mainly as 
lipid-lowering drugs but pleiotropic actions are also present. Healthy lifestyle, on the other hand, is effective and inexpensive 
and has no harmful effects. Five items are associated with lower cardiac risk: non-smoking, BMI ≤25, regular exercise (30 min/
day), healthy diet (fruits, vegetables, low-saturated fat, and 5-30 g alcohol/day). Nevertheless, there are difficulties in implement-
ing these measures both at the individual and population levels. Changes in behavior require multidisciplinary care, including 
medical, nutritional, and psychological counseling. Participation of the entire society is required for such implementation, i.e., 
universities, schools, media, government, and medical societies. Although these efforts represent a major challenge, such a 
task must be faced in order to halt the atherosclerosis epidemic that threatens the world.
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Cardiovascular disease (CVD) is the main cause of 
death in Brazil, as well as in the world, including rich and 
poor countries. One century ago, CVD accounted for less 
than 10% of all deaths worldwide, while today it is respon-
sible for approximately 30%, including nearly 40% of deaths 
in high income countries and about 28% in countries with 
low or average income (1).
In Brazil, mortality from CVD is estimated to be 33% (2). 
Of note is the increase in the number of elderly individuals, 
especially over 80 years of age. Such group accounted for 
0.32% of the general population in the USA in 1950, as 
opposed to 0.74% in 1990 (an increase of over 130%). In 
Brazil, this group represented 0.4% of the general popula-
tion in 1980 and 0.9% in 2001. Furthermore, in 2000, ap-
proximately 15% of the population was 50 years of age or 
older. This percentage is expected to reach 42% by 2050. 
As the Brazilian population gets older, non-communicable 
diseases will burden the health care system, and the costs 
associated with such diseases already account for half 
the costs of all hospital admissions. Non-communicable 
diseases account for 66% of all diseases, while contagious 
diseases account for 24% and injuries for 10% (2). This 
rate of non-communicable diseases is not necessarily an 
inevitable result of modern society, but rather a problem 
that can be avoided. The main factors behind most of these 
diseases, i.e., coronary artery disease (CAD), stroke, diabe-
tes, and several types of cancer, are not genetic but rather 
environmental and behavioral. Atherosclerosis in particular 
is responsible for most cardiovascular events. 
Atherosclerosis is a chronic inflammatory and prolifera-
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tive disease, which may cause obstructions of the coronary, 
cerebral and peripheral arteries. Atherosclerosis tends to 
be a progressive process that begins early in life, probably 
in childhood. It is typically multifactorial in origin, most often 
dependent on risk factors such as hypercholesterolemia, 
diabetes, smoking, hypertension, sedentarism, and obe-
sity. Atherosclerosis results from a complex interaction of 
hemodynamic and biochemical factors and is determined 
by circulating blood cells, endothelial cells, smooth muscle 
cells, blood lipids, and connective tissue of the arterial 
wall. Once considered to be the result of fat deposition in 
the arterial wall, it is now viewed as an inflammatory and 
proliferative process that can lead to arterial wall thickening 
and eventual complete obstruction that hampers myocardial 
blood flow, thus causing the clinical syndromes of angina 
or infarction (3). These mechanisms, however, are not the 
subject of this paper.
As far as clinical evolution is concerned, coronary 
atherosclerosis has two distinct phases (Figure 1): the 
asymptomatic phase that may begin at birth and proceed 
until mid-life when symptoms occur. This phase is usually 
associated with non-obstructive lesions. However, some 
of these lesions may suffer acute instabilization due to 
plaque rupture, with partial or total occlusions, causing 
acute coronary syndromes or infarction.
The symptomatic phase is characterized by flow limit-
ing, advanced lesions and is associated with classical 
clinical manifestations such as effort angina, heart failure 
or myocardial infarction (MI). Hence, this is the phase that 
more commonly causes com-
plications.
Until recently, most medical 
efforts were directed towards the 
symptomatic phase, including 
diagnostic procedures and treat-
ments. Lately, more emphasis 
has been placed on identifying 
patients in the early, asymp-
tomatic phase. Thus, several 
biomarkers and noninvasive 
imaging techniques have been 
developed whose main goal 
is to identify individuals in the 
early stages of atherosclerosis, 
in order to avoid its progression 
or even to prevent its develop-
ment.
CAD is responsible for 
most clinical complications of 
atherosclerosis. Its treatment is 
basically covered by four types 
of interventions: 1) coronary sur-
gery; 2) percutaneous coronary 
interventions; 3) drug treatment; 
4) lifestyle modification. 
The first two focus on CAD complications, such as angina 
or infarction, do not interfere with the biochemical nature 
of the disease. Drugs and healthy lifestyle, on the other 
hand, not only can prevent disease development but can 
also prevent complications, reduce or abolish progression 
and even induce plaque regression.
The choice of either approach or of a combination of the 
two has major implications, including effectiveness, costs, 
adherence, and side effects. The purpose of this article is to 
compare these two latter approaches, drug treatment and 
lifestyle modification, highlighting the peculiarities of each 
one and offering practical suggestions for physicians. 
Drugs
Ancel Keys, in his landmark Seven Countries Study 
published in 1966 (4), observed that cardiac mortality was 
directly associated with fat consumption in different coun-
tries; the more fat people ate, the greater was coronary 
mortality. In 1961, Kannel et al. (5) showed a direct asso-
ciation between plasma cholesterol and cardiac mortality 
in the Framingham Study, with mortality also substantially 
increasing with increasing blood pressure. These two fun-
damental clinical observations followed the original dis-
coveries of the Russian investigators Anichkov, Ignatowski 
and Chalatov (6) who, in the early 1900’s, fed rabbits with 
milk and eggs and demonstrated that atherosclerosis was 
produced only by egg cholesterol. Although it took about 
50 years for these basic discoveries to reach the clinical 
Figure 1. Spectrum of human atherosclerosis. Although most clinical manifestations occur at 
middle age, the disease actually begins at birth and has a long asymptomatic period (see text). 
AMI = acute myocardial infarction; ACS = acute coronary syndrome; CAD = coronary artery 
disease.
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arena, when they finally did, their impact was immense and 
changed medical research and practice forever. Several 
epidemiological studies subsequently confirmed these 
relationships, which covered a wide range of cholesterol 
concentrations, including those considered to be normal 
or mildly elevated. Both drug therapy and diets began 
to be tested to ascertain whether they could change the 
natural history of atherosclerosis. Definitive assessment of 
whether LDL reduction would be beneficial was facilitated 
by the development of potent cholesterol-lowering drugs, 
the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, termed statins. Since then a series 
of studies have demonstrated their efficacy in preventing 
major cardiovascular events.
Secondary prevention
Patients who had already experienced coronary events, 
those at particularly high risk for events, namely diabetics 
and patients with peripheral artery disease, were the initial 
natural focus. Some of the most important trials are sum-
marized here. 
In the Multiple Risk Factor Intervention Trial (MRFIT) 
(7), 69% of deaths from CAD in the first 6 years of follow-
up occurred in subjects with total cholesterol (TC) between 
182 and 264 mg/dL. In the first 16 years of the Framingham 
Heart Study, 40% of participants who developed MI had 
TC levels between 200 and 250 mg/dL.
All-cause mortality was significantly reduced, due 
mainly to a significant 18% decrease in coronary deaths. 
The authors concluded that adding simvastatin to existing 
treatments safely produced substantial additional benefits 
for a wide range of high-risk patients, irrespective of their 
initial cholesterol concentrations.
In the Scandinavian Simvastatin Survival Study (7) the 
HMG-CoA reductase inhibitor simvastatin reduced total 
mortality in patients with CVD by 30% mainly due to a 42% 
reduction in deaths from CAD. The secondary endpoint, 
analyzed by time of first event, was “major coronary events”, 
which comprised coronary deaths, definite or probable 
hospital-verified non-fatal acute MI, resuscitated cardiac 
arrest, and definite silent MI verified by electrocardiogram. 
Simvastatin produced highly significant reductions in the 
risk of death and morbidity for patients with coronary heart 
disease (CHD) followed for a median tie of 5.4 years. The 4S 
study also provided evidence for a beneficial effect of sim-
vastatin on fatal plus nonfatal cerebrovascular events. 
Subsequently, in the CARE Trial (7), another statin 
- pravastatin, was shown to reduce fatal and nonfatal 
coronary events in patients with CAD. The purpose of the 
CARE Trial was to investigate whether the benefit achieved 
by lowering the LDL cholesterol levels of patients who had 
hypercholesterolemia could be extended to patients with 
CAD and average LDL. The results showed that reducing 
LDL cholesterol from average to low levels (from a mean 
of 139 to a mean of 97 mg/dL) significantly decreased 
recurrent coronary events. The magnitude of the risk 
reduction was consistent for the major end points of myo-
cardial infarction, i.e., coronary death, bypass surgery and 
angioplasty. However, there was no significant reduction 
in overall mortality. 
In addition, the CARE Trial showed that patients 60 
years old or older, women and those with impaired left 
ventricular ejection fraction, in all of whom the efficacy 
of lowering cholesterol levels had been questioned, also 
experienced a similar risk reduction. Stroke, a specified 
endpoint in the CARE Trial, was significantly reduced 
by 31% in the pravastatin group. This agreed with the 
reduction in cerebrovascular endpoints found in post hoc 
analyses of data from several previous trials conducted 
in hypercholesterolemic populations. A meta-analysis of 
pravastatin trials in patients with atherosclerosis showed 
a significant 62% reduction in stroke. 
The long-term intervention with pravastatin in ischemic 
disease (LIPID Study) (7) was another study with pravas-
tatin, which provided evidence that lowering cholesterol 
levels with statin in patients with a broad range of initial 
cholesterol levels and a history of MI or unstable angina 
reduced the risk of death from CAD, CVD, and all causes 
combined. In addition, the risk of MI or stroke was signifi-
cantly reduced. 
These results extended the findings of the 4S, which 
showed that treatment had benefits in terms of mortality 
from CHD and overall mortality among patients with CHD 
who had a mean cholesterol level of 261 mg/dL at study 
entry. In the LIPID Study, results demonstrated similar 
benefits in patients with a mean cholesterol level about 44 
mg/dL lower than in 4S. 
The LIPID Study also extended the findings of the CARE 
Study, which had shown a reduction in the composite death 
outcome due to CAD and nonfatal MI in patients with CAD 
with a similar mean cholesterol level of 209 mg/dL at entry; 
mortality, also was reduced.
The heart protection study (HPS) (7), a large British 
study of about 20,536 patients who were cared for by their 
attending physicians, demonstrated more than a 20% re-
duction in vascular events in patients with prior MI, stroke, 
peripheral vascular disease, or diabetes and TC levels as 
low as 135 mg/dL, a substantial number of whom had LDL 
under 100 mg/dL. By implication, this result suggests that 
these agents may work by additional mechanisms that 
are unrelated to lipid lowering. Some investigators have 
suggested that statins also have pleiotropic properties, 
such as modulation of inflammation within the arterial wall, 
that may contribute to their beneficial effect. In the Anglo-
Scandinavian Cardiac Outcomes Trial (Ascot) (7), 19,342 
subjects aged 40 to 79 years, with hypertension and at least 
three other cardiovascular risk factors were randomized to 
one of two antihypertensive regimens. The lipid-lowering 
arm included 10,305 subjects with TC of 6.5 mM or less 
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who were randomized to receive 10 mg atorvastatin in 
addition to their anti-hypertensive treatment, or placebo. 
The primary endpoints were death from CHD and nonfatal 
heart attack. After 3.3 years, atorvastatin had shown clear 
benefits over placebo, yielding a relative risk reduction of 
36%. Additional benefits were reduced risk of stroke, total 
cardiovascular events, and total coronary events.
These and other well-conducted studies firmly estab-
lished that cholesterol lowering, independently of baseline 
values, reduced cardiovascular events in a broad population 
spectrum, including those who suffered previous events 
and those at high risk as well.
Primary prevention
The fact that the benefit from LDL reduction in patients 
without clinical CAD (primary prevention) extends to in-
dividuals with average serum cholesterol levels, women, 
diabetics, smokers, and older persons was observed in the 
Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) (8). A cohort of healthy middle-aged 
and older men and women with average TC and LDL levels 
and with below-average HDL-C levels was studied.
The primary endpoint was the incidence of first acute 
major coronary events, fatal or nonfatal acute MI (AMI), 
unstable angina, or sudden cardiac death. Treatment with 
lovastatin resulted in a 37% reduction in the risk for first acute 
major coronary events, defined as fatal or nonfatal AMI, 
unstable angina or sudden cardiac death. The differences 
between the two treatment groups appeared as early as 
after one year. Analysis of secondary endpoints confirmed 
that the composite primary endpoint was representative of 
its components: lovastatin therapy significantly reduced the 
risk for fatal or nonfatal AMI by 40% and the risk for unstable 
angina by 32%. Risk reduction with lovastatin across the 
spectrum of cardiovascular events was further confirmed 
by a 33% risk reduction in the need for revascularizations 
and 25% risk reductions in both total cardiovascular and 
total coronary events. 
The West of Scotland Coronary Prevention Study 
(WOSCOPS) (8) was a double-blind study designed to 
determine whether the administration of pravastatin to men 
with hypercholesterolemia and no history of MI reduced 
the combined incidence of nonfatal AMI and death from 
CAD. A total of 6595 subjects underwent randomization. 
Pravastatin lowered plasma TC levels by 20%, LDL by 
26%, and triglycerides (TG) by 12%, whereas HDL was 
increased by 5%. There were no such changes with pla-
cebo. Reductions in all-cause and CAD mortality were not 
significant; noncardiovascular death, including death from 
cancer, trauma or suicide, did not differ between groups. 
Compared to placebo, statin treatment reduced the risk of 
fatal or nonfatal coronary events by approximately 30%. 
These two major trials lend support to the concept that 
hypercholesterolemia alone, even in the absence of overt 
CAD, deserves treatment both in men and women.
Acute phase
Patients suffer the highest rate of death and recurrent 
ischemic events during the early period after an acute 
coronary syndrome (ACS), but when the Myocardial Isch-
emia Reduction with Aggressive Cholesterol Lowering Trial 
(Miracle) (7) was designed it was not clear whether early 
initiation of treatment with a statin could reduce the occurrence 
of early events. Thus, Miracle sought to determine whether 
treatment initiated 24 to 96 h after an ACS reduces death 
and nonfatal ischemic events. A total of 3086 adults aged 18 
years or older with unstable angina or non-Q-wave AMI were 
stratified and randomly assigned to receive treatment with 
atorvastatin (80 mg/day) or matching placebo after hospital 
admission. Atorvastatin reduced recurrent ischemic events 
over a 16-week period of treatment. There was a 2.6% ab-
solute reduction and a 16% relative reduction in the primary 
combined endpoint of death, nonfatal AMI, cardiac arrest with 
resuscitation, or worsening symptomatic myocardial ischemia 
with objective evidence and emergency rehospitalization. 
Although the study was not powered to assess mortality, it 
did show beneficial effects of atorvastatin on ACS.
The pravastatin or atorvastatin evaluation and infection 
therapy-thrombolysis in MI (Prove It-Timi Trial) (9) was de-
signed to compare the standard degree of LDL cholesterol 
lowering to approximately 100 mg/dL with 40 mg pravastatin 
daily with more intensive LDL cholesterol lowering to ap-
proximately 70 mg/dL with 80 mg atorvastatin daily as a 
means of preventing death or major cardiovascular events 
in patients with ACS. 
The more intensive regimen resulted in a lower risk of 
death from any cause or major cardiac events than did a 
more moderate degree of lipid lowering. Intensive therapy 
with atorvastatin resulted in a median LDL cholesterol level 
of 62 mg/dL compared with 95 mg/dL for standard-dose 
pravastatin. Intensive therapy had a consistent beneficial 
effect on cardiac events, including a significant 29% reduc-
tion in the risk of recurrent unstable angina and a 14% 
reduction in the need for revascularization. The reduction 
in the rate of death from any cause was of borderline 
significance (28%, P = 0.07), suggesting that more ag-
gressive lipid lowering is important not only to reduce the 
risk of recurrent ischemia, but possibly also to decrease 
the risk of fatal events.
Reduction of clinical events with more intensive lipid-
lowering therapy was apparent as early as 30 days after 
the beginning of therapy. This reduction was similar to that 
reported with statin treatment in the placebo-controlled 
Miracle Trial. These data corroborated previous observa-
tions that patients with ACS can particularly benefit from 
early and intensive lipid-lowering therapy with statins. Acute 
LDL lowering by statins and simultaneous improvement in 
endothelial function have also been demonstrated. Based 
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on these observations, it is now generally accepted that 
statin therapy should be used in ACS, provided LDL is 
elevated.
Plaque regression
Whether regression of established coronary lesions 
can be achieved by any means is a key question. Earlier 
studies (10) relied on coronary angiography and as-
sessed effects of various interventions including diets, 
exercise, surgical ileal shunt, as well as not so potent 
lipid-reducing drugs such as colestipol, colestiramine, 
niacin, and lovastatin. In the last decade, when imaging 
techniques for plaque evaluation were developed and 
more potent anti-lipidemic drugs became available, in-
vestigations of this issue regained impetus. Studies such 
as asteroid (11), reversal (12), meteor (13), and atheroma 
(14) investigations addressed this question, sharing the 
following characteristics: 1) analysis of plaque volume by 
intracoronary ultrasound and of carotid intima/thickness 
by ultrasound or magnetic resonance imaging; 2) use of 
potent statins including atorvastatin and rosuvastatin; 3) 
consistent and large LDL reductions, usually to 70-80 
mg/dL associated with significant increases in HDL; 4) 
follow-up of about 2 years with a sufficient number of 
patients who were carefully monitored; 5) randomization 
with appropriate controls and treatment groups. Figure 2 
shows the results of the Meteor study.
In these circumstances, all investigators observed that 
major lipid lowering induced slower lesion progression or 
even plaque regression. The most significant finding seemed 
to be plaque stabilization in the treatment groups while 
lesion progression occurred uniformly among untreated 
controls. It is estimated that regression may occur in up to 
20-25% of cases.
An alternative strategy to modify atherosclerotic evolu-
tion was tested by Nissen et al. (15), who administered 
recombinant ApoA-I Milano to CAD patients, avoiding 
atherosclerosis progression. Indeed, plaque volume as 
assessed by intracoronary ultrasound was reduced com-
pared to controls. This strategy, however, is cumbersome, 
but the study’s contribution must be taken as a proof of 
concept.
These impressive observations indicating that major 
lipid reductions by statins may indeed impact the nature of 
the atherosclerotic process, leading to plaque stabilization 
or even regression, have major significance for medical 
practice. The phenomenon of regression has been con-
vincingly demonstrated for the first time in the history of 
atherosclerosis. These studies lend support to the notion 
that medical treatment is in fact extremely efficacious; indeed 
it is the only way by which the biochemical atherosclerotic 
process can be slowed. Whether it could be interrupted on 
a long-term basis, or even totally prevented, will depend 
on future investigations.
How low is sufficient?
The value of reducing LDL cholesterol levels substan-
tially below 100 mg/dL in patients with CAD, particularly 
among those with stable disease, was demonstrated in the 
TNT Trial (7). In the TNT Trial, a total of 10,001 patients 
underwent randomization and received double-blind treat-
ment with either 10 or 80 mg atorvastatin. The relative risk 
reduction of the primary composite endpoint of death from 
CAD, nonfatal non-procedure-related MI, resuscitation after 
cardiac arrest, and fatal or nonfatal stroke was 22% in the 
group given 80 mg atorvastatin, compared to the group 
given 10 mg of atorvastatin. 
The TNT Trial provided evidence that the use of intensive 
therapy to reduce LDL cholesterol levels below 100 mg/
dL is associated with substantial clinical benefit in patients 
with stable CAD. Both atorvastatin groups had low rates of 
CAD events. The rate for the group given 10 mg atorvastatin 
was lower than the rates reported with statin treatment in 
placebo-controlled, secondary prevention trials of popula-
tions with a baseline risk similar to that of TNT patients.
Cholesterol Treatment Trialists (7) also examined this 
question and their results showed an approximately lin-
ear relationship between the absolute reductions in LDL 
cholesterol and proportional reductions in the incidence of 
coronary and other major vascular events. This finding is 
reinforced by those of some direct randomized comparisons 
of different statin regimens, which also indicate that larger 
LDL cholesterol reductions produce larger reductions in 
vascular disease risk. 
Figure 2. Evolution of carotid intima/media thickness (CIMT) 
during 24 months of treatment with rosuvastatin compared to 
placebo. Statin treatment stabilized carotid plaques. Repro-
duced with permission from Ref. 13.
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Reductions were similar irrespective of pretreatment 
cholesterol concentrations or other characteristics - age, 
gender, or pre-existing disease - of the study participants. 
A 1 mM reduction in LDL cholesterol that is sustained for 5 
years may well produce a proportional reduction in major 
vascular events of about 23%.
A recent meta-analysis (16) involving 170,000 patients 
in 26 trials also demonstrated that lower LDL levels are 
indeed associated with greater reductions in CVD events. 
Furthermore, Forrester (17), analyzing experimental and 
clinical evidence, suggested that normal LDL values for 
humans are ≤70 mg/dL. Current practice, therefore, holds 
that LDL should be lowered to about 70 or even less, at 
least for secondary prevention. For primary prevention most 
guidelines endorse ≤100 mg/dL as an acceptable value. 
Inflammation
Since atherosclerosis is an inflammatory disease and 
elevated inflammatory markers such as high-sensitivity 
C-reactive protein (hsCRP) indicate a poor prognosis, a 
question has been raised regarding the possible value of 
reducing hsCRP in patients without overt hypercholester-
olemia. Accordingly, Ridker et al. (18) in the Jupiter Trial, 
examined this issue in 17,802 men and women without 
known CAD, who had normal cholesterol levels but signs 
of systemic inflammation (high hsCRP) and they observed 
that rosuvastatin could cut in half the risk of heart attack 
or stroke. 
Individuals with elevated hsCRP who are otherwise 
at a 5 to 10% or 10 to 20% 10-year risk had substantive 
absolute risk reductions, suggesting that this group might 
well be considered candidates for statin therapy. They 
also demonstrated that men and women estimated to be 
at low risk (5% 10-year risk estimates) had low absolute 
risk reductions and hence represent a group for which the 
absolute benefit of statin therapy is small. However, the 
issue of how important isolated high CRP is remains con-
troversial and further studies are needed until a definitive 
answer is obtained.
Long-term effects
A concern about statin treatment is their long-term ef-
fects. Most clinical trials have only a duration of 4-5-years, 
which is too short an observational period, considering the 
life-long duration of atherosclerosis. A recent observation 
has shed some light on this question.
Long-term data obtained in the WOSCOPS over a pe-
riod of 16 years (19) have been reported. Men prescribed 
statin therapy for 5 years during the clinical trial had fewer 
cardiovascular events a decade later, although a majority 
of the study cohort stopped taking their cholesterol-lowering 
medication. Over the post-trial period, when treatment 
was under the control of the patients and their physicians, 
a statistically significant reduction in death from CHD or 
nonfatal AMI remained among treated patients compared 
to placebo-treated individuals. The results, according to the 
authors, were presumably due to the stabilization of existing 
plaque and a slowing of the progression of CAD.
However, the problem concerning the long-term effects 
of statins remains largely unresolved and is especially perti-
nent to young patients who need long-lasting treatments.
Low HDL
Treatment of abnormally low HDL levels is more difficult 
but potentially very significant as the role of HDL as target 
for therapy is being increasingly recognized. High doses 
of oral niacin (2-3 g/day or more) may be effective. A trial 
conducted on post-infarction patients has demonstrated that 
an increase in HDL-C levels obtained with gemfibrozil (600 
mg twice daily) in patients with relatively low LDL-C levels 
prolongs reinfarction-free survival (20). We (21) also gave 
niacin to patients with low HDL and measured endothelial 
function after three months. Although niacin did not increase 
total HDL during this short period, endothelial function was 
improved in every patient, suggesting that niacin improved 
HDL function.
The ApoA-I Milano Trial (15) involved 57 ACS patients 
in a randomized, placebo-controlled trial. Intravenous re-
combinant ApoA-I Milano/phospholipid complex produced 
a significant regression of coronary atherosclerosis as 
measured by intravascular ultrasound, presumably related 
to an increase in reverse cholesterol transport from ather-
omatous lesions to the serum with subsequent removal 
by the liver.
In summary, statin therapy has definitive beneficial ef-
fects both in terms of secondary and primary prevention: 
it reduces overall cardiovascular events, including cardiac 
death, fatal and nonfatal AMI, stroke and the need for revas-
cularization. These benefits were shown in men and women 
alike and irrespective of hypertension, diabetes, smoking 
habits, and also in the elderly. No increase of cancer was 
documented. Therefore, statin is the most valuable drug 
for the treatment of atherosclerosis. 
Unresolved issues in statin therapy 
As shown in Figure 3, there are many unresolved issues 
regarding statins. For instance, residual risk (Figure 4) after 
successful treatment has been reported to be about 65% in 
most studies. This means that, although highly significant 
from a statistical point of view and biologically meaningful 
as well, total cardiovascular risk is far from eliminated. Ide-
ally, a treatment should eradicate a disease as done, for 
instance, with antibiotics when pneumonia is successfully 
treated. Hence, there is considerable room for improvement 
in atherosclerosis treatment. Possibly, adequate measures 
to correct lifestyle behavior are indicated. Another major 
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problem is the long-term use of statins in young individu-
als; neither long-term effects nor side-effects have been 
adequately assessed. Therefore, judicious evaluation of 
risks/benefits must exerted by physicians on individual 
cases. Similarly, the issue of costs is fundamental giving 
the prevalence of atherosclerosis in 
poor countries. Remaining unresolved 
issues are self-evident as shown in 
Figure 3. 
Other drugs
Renin-angiotensin system block-
ade by angiotensin-converting en-
zyme (ACE) inhibitors or by an 
angiotensin II (Ang II) subtype 1 re-
ceptor antagonist has been expanded 
beyond patients with heart failure or 
left ventricular systolic dysfunction. 
Important observations come from 
randomized controlled studies like the 
Heart Outcomes Prevention Evalu-
ation (HOPE) Trial (22). The HOPE 
Trial demonstrated that the ACE inhibitor ramipril reduced 
fatal and nonfatal vascular events by 20-25% in patients 
at high risk, including diabetics with additional risk factors 
or patients with clinical coronary, cerebral, or peripheral 
arterial atherosclerotic disease. In another study of the anti-
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Figure 4. Residual risk in primary and secondary prevention studies. Note that the residual risk ranges from 58 to 79%. WOSCOPS = 
the West of Scotland Coronary Prevention Study (7). AFCAPS/TexCAPS = the Air Force/Texas Coronary Atherosclerosis Prevention 
Study (7); HPS = Heart Protection Study (7); 4S = Scandinavian Simvastatin Survival Study (7); CARDS = the Collaborative Atorvas-
tatin Diabetes Study (7); LIPID = the Long-Term Intervention with Pravastatin in Ischemic Disease Study group (7); TNT = intensive 
lipid lowering with atorvastatin in patients with stable coronary disease; Treating to New Target Investigators (7); CARE = the effects 
of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent 
Events Trial investigators (7).
Figure 3. Potential problems regarding statins use. See text.
Unresolved Issues in Statin Therapy
Statins:
• Reduce only part of the risk
• There are side effects and intolerance
• Frequently need associations
• Long-term adherence is a problem
• Long-term effects in young people
• Lipids beyond LDL-HDL, Lp(a)
• Patients without dyslipidemia
• High costs - poor people cannot afford statin treatment; but 
cardiovascular disease is the main cause of death, in rich and poor 
countries alike
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inflammatory effects of Ang II subtype 1 receptor blockade 
in hypertensive patients with microinflammation (EUTOPIA) 
(23), the Ang II subtype 1 receptor antagonist olmesartan 
significantly reduced vascular microinflammation in patients 
with essential hypertension. Patients with essential hyper-
tension were a population at high risk similar to that in the 
HOPE Trial (22), with atherosclerotic disease and/or the key 
components of metabolic syndrome (e.g., type 2 diabetes 
mellitus and/or hyperlipidemia) in most cases. This was 
reflected by a rather high level of microinflammation and 
a mean baseline serum hsCRP concentration of 4.5 mg/L 
in both treatment groups. After 12 weeks of therapy with 
olmesartan, hsCRP was reduced by 20%, whereas blood 
pressure reduction in the placebo treatment group had only 
a minor or no effect on inflammation markers. Thus, the 
beneficial cardiovascular effects documented for inhibitors 
of the renin-angiotensin system (e.g., ACE inhibitors and 
Ang II receptor antagonists) could be attributed, at least in 
part, to their anti-inflammatory action independent of the 
blood pressure-lowering effect. 
Antiplatelet therapy is another very effective preventive 
measure. For instance, aspirin reduces the incidence of MI 
in males over the age of 50 years. Whether this approach 
should be employed in the general population or only in 
patients at high risk is unclear, and the optimal dosage is not 
known. A prudent approach would be to administer 81-325 
mg daily to men with multiple coronary risk factors.
Fibrates can increase HDL and are especially effective in 
hypertriglycidemia. The Veterans Administration-High-Den-
sity Lipoprotein Intervention Trial (24) showed that fibrate 
treatment reduced the risk of a recurrent coronary event by 
25% in patients with CAD, low HDL, modestly elevated TG, 
and normal LDL. Low HDL-C associated with elevated TG-
rich lipoproteins and their remnants represents an important 
therapeutic target. Obesity, metabolic syndrome, and type 
2 diabetes are intimately associated with an atherogenic 
phenotype featuring low HDL-C combined with elevated 
TG-rich lipoproteins and small dense LDL. Hence, there 
is great interest in treatment strategies involving niacin, 
fibrates or their association to treat dyslipidemia. Niacin is 
especially potent in raising HDL and is more efficacious in 
raising HDL-C than fibrates; but niacin and fibrates compa-
rably reduce TG-rich lipoproteins and LDL. Niacin is also 
effective in lowering lipoprotein levels. 
Healthy lifestyle 
An unhealthy lifestyle has devastating effects on survival, 
as shown by Peto et al. (25), who compared non-obese 
Americans to moderately and morbidly obese individuals, 
and smokers to non-smokers. The authors noticed that both 
conditions severely reduced life expectancy, reaching an 
incredible 10-year span among smokers. In the Whitehall 
Study (26), 19,019 male civil servants were followed for 
38 years in London. A 10- to 15-year shorter life expec-
tancy was observed among high-risk individuals, i.e., those 
with all three risk factors: smoking, hypertension and 
hypercholesterolemia. Similar reductions occurred with 
other risk factors such as diabetes. Unfortunately, most 
lay people as well as many doctors are not aware of these 
impressive figures!
Several studies have compared the effects of lifestyle 
interventions to those obtained with drug treatment in coro-
nary disease. Ford et al. (27) reported on 10 such studies, 
as shown in Figure 5. It can be seen that interventions on 
risk factors were more effective in reducing mortality than 
all drugs and invasive procedures in the USA as well as 
in different European countries. Of particular note are the 
studies in Finland where a national and meticulous program 
was implemented (see ahead). 
Eating habits 
Diets 
Countless studies on diets have been published (28) 
and the Mediterranean diet has been especially analyzed. 
The Mediterranean diet is characterized by low-saturated 
fat, high intake of vegetables, fruits and legumes plus olive 
oil and mild/moderate wine consumption. It is traditional in 
Mediterranean countries, especially Spain. Several studies 
were designed to test its efficacy. The PREDIMED Study 
(28) demonstrated the beneficial effects of a Mediterranean 
diet on risk factors, including inflammatory markers, glucose 
and blood pressure. 
de Lorgeril et al. (29) carried out the Lyon Diet Heart 
Study in which 605 post-MI patients were randomly assigned 
to the prudent Western-type diet or to a Mediterranean diet 
during a mean follow-up of 46 months. The Mediterranean 
diet significantly reduced the combined endpoint of cardiac 
death, nonfatal AMI and noncardiac death. 
The EPIC Trial (30) is an observational study of 22,043 
adults who were followed for an average of 44 months in 
Greece. The effects of the Mediterranean diet on mortality 
were analyzed according to adherence to the diet using a 
well-defined score. Individuals who most adhered to the 
diet experienced a 25% reduction in general mortality, a 
33% decrease in mortality due to CAD and a 24% decrease 
in cancer mortality. Trichopoulou et al. (31) estimated the 
contribution of each component of the Mediterranean diet 
in the EPIC Study regarding its overall effect on mortality 
and concluded that high intake of legumes/fruits and mono-
unsaturated fats each contributed about 10%; high intake 
of vegetables and low meat, 16%, and moderate alcohol 
consumption about 23%.
Sabaté et al. (32) studied the effects of nuts consumption 
on blood lipids in a pooled analysis of 25 trials in 7 coun-
tries. With a mean consumption of 67 g/day, nuts reduced 
cholesterol by 5.1%, LDL by 7.4%, and the LDL/HDL ratio 
by 8.3%, while TG was reduced by 10.2% in individuals 
whose TG levels were at least 150 mg/dL. The effects 
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were dose related and different nuts had similar effects on 
blood lipids. Interestingly, effects were greatest in people 
with high baseline LDL and low body mass index (BMI) and 
among those on Western-type diets. Nuts are rich in plant 
protein (10-25%) and unsaturated fatty acids (50-75%) in 
addition to minerals, fiber and vitamins; therefore they are 
excellent nutritional complements.
As mentioned earlier, high-fat diets are notoriously detri-
mental. In North Karelia, Finland, a program was launched 
aimed at the adoption of a healthy diet and progressively 
extended to the entire country (33). From 1982 to 2007, 
total dietary fat was reduced to about 30%, saturated fat 
was maintained at about 10%, monounsaturated fat at 10-
15%, and polyunsaturated fat at 5-10%. As a consequence, 
coronary and total mortality declined by an amazing 85%. 
Universities and several entities were involved in this 
program. Although Finland is a peculiar country because 
of its small size and highly educated citizens, this study is 
a proof of concept showing that major population lifestyle 
changes can be achieved. 
High carbohydrate consumption is also a major source 
of calories and is presently recognized as a significant, if 
not the most important cause of inadequate diets world-
wide. Effects of glucose overload have been meticulously 
investigated. O’Keefe et al. (34) studied the effects of a 
glucose-rich meal on plasma glucose, oxidative stress, 
endothelial function, and inflammation. They documented 
that variation in plasma glucose correlated directly with 
oxidative stress, increased CRP and decreased arterial 
endothelium dilation. But they also documented that the 
glucose increase could be substantially reduced by simul-
taneous ingestion of red wine, almonds, vinegar, and whey 
protein but was not affected by beer and gin, suggesting 
that this postprandial glucose increment is amenable to 
simple dietary interventions.
Regarding the efficiency of different types of diet, Sacks 
et al. (35) compared diets high and low in saturated fats, 
carbohydrates or proteins regarding their ability to induce 
weight loss in 811 overweight individuals followed for 2 
years; they all reduced body weight comparably by about 
4 kg. The data indicate that reduction in caloric intake is the 
dominant factor regardless of how it is achieved. 
Based on these findings, there is general consensus 
that the Mediterranean diet is indeed effective and possibly 
the most adequate for CVD prevention. Initiatives to correct 
unhealthy dietary habits, both at the individual and popula-
Figure 5. Comparison of treatments with drugs and interventions vs risk factor modifications. Note that overall lifestyle interventions 
are more efficient. Reproduced with permission from Ref. 27.
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tion levels, are generally frustrating. Initial gains in weight 
reductions for instance, are frequently overcome by weight 
regain over the next 1 to 2 years.
Salt is another fundamental component of the Western 
diet and is responsible in part for one major risk factor, i.e., 
hypertension which, on the other hand, is a major contributor 
to a devastating event, i.e., stroke. Even small increases 
in blood pressure cause a considerable increase in cardio-
vascular events in both women and men (36).
Tuomilehto et al. (37), in a study from Finland comparing 
higher and lower salt intake in 2436 men and women, 25 
to 64 years old, observed that higher salt intake increased 
coronary, cardiovascular and all deaths. 
In the Intersalt Study, Perry and Beevers (38) observed 
that, in different countries, mortality due to stroke, is directly 
proportional to salt excretion in urine, which reflects salt 
ingestion. 
Joossens and Kesteloot (39), in a single epidemio-
logical investigation, observed that systolic blood pressure 
increased steadily as people aged among populations that 
added salt to their diet, such as Americans and Europe-
ans; on the contrary, among primitive populations such as 
the Yanomani and Carajas Indians of Brazil, who did not 
add salt to their diets, blood pressure remained the same 
through ages 20 to 69. 
The impact of dietary salt reduction has been a constant 
preoccupation. Bibbins-Domingo et al. (40) calculated the 
impact of small reductions of salt intake on CVD over a 
one-year period. In this interesting simulation, the authors 
investigated the implications of a 3.0-g reduction in salt 
ingestion in individuals aged 35 to 84 years regarding 
incidence of CAD, total MI, incidence of stroke, and total 
death among non-black men and women as well as in black 
men and women. There were significant reductions in all 
parameters and a huge saving in money expenditure. 
Hence there is a plethora of evidence indicating that 
high-salt ingestion is deleterious and that even a small salt 
reduction such as 3-5 g/day has the potential to prevent 
cardiovascular events. In practice, a low-salt diet of ≤4.0 
g/day is usually recommended for hypertension. In heart 
failure patients, even smaller amounts may be needed.
Trans-fatty acids
Trans-fatty acids (TFA) ingestion has been associated 
with CAD (41). TFAs result from hydrogenation of fish and 
vegetable fats for industrial purpose, or else from natural 
digestion in ruminant animals. Usually they are measured in 
adipose tissue, whole blood or red blood cell membranes. 
Increased TFA ingestion has consistently been associated 
with worsening blood lipid profile, both LDL and HDL, in 
men and women as well, in a dose-dependent manner. 
They induce expression of inflammatory markers, increase 
insulin resistance and cause endothelial dysfunction (41). 
Hence, the metabolic milieu, which favors the development 
of atherosclerosis is induced and this is strong evidence 
of biological plausibility of an association between TFA 
intake and CVD.
On the other hand, the direct relationship between TFAs 
and CAD is less robust and has been deemed as “probable” 
in evidence-based guidelines (42). From our point of view, 
the evidence regarding lipids is unquestionable. Regarding 
CAD, the demonstration of a cause/effect relationship has 
been hampered by the long observational period needed to 
prove it in humans. However, as mentioned earlier, its bio-
logical plausibility is clear. Under these circumstances, we 
would favor the removal of TFAs from the food supply. 
Marine fatty acids
About three decades ago, Bang et al. (43) reported that 
serum cholesterol and TG were lower in Greenland Inuits 
than in age-matched Danes, despite consumption of a diet 
very low in fruits, vegetables, and complex carbohydrates 
and high in fat and cholesterol. Kromann and Green (44) 
further reported that acute MI rates in this same population 
were markedly lower than those in Denmark. Sekikawa et 
al. (45) studied 281 Japanese born and living in Japan, 
306 white Americans living in the USA, and 281 Japanese-
American men, i.e., Japanese men born and living in the 
USA, ages 40 to 49 years, regarding marine fatty acid 
consumption and atherosclerosis incidence. Japanese men 
had the lowest levels of atherosclerosis, whereas whites 
and Japanese Americans had similar levels. Japanese had 
2-fold higher levels of serum marine-derived n-3 fatty acids 
than whites and Japanese Americans living in the USA. 
Very high levels of marine-derived n-3 fatty acids have 
antiatherogenic properties that are independent of traditional 
cardiovascular risk factors and may contribute to reducing 
the burden of atherosclerosis in the Japanese, a lower 
burden that is unlikely to be the result of genetic factors.
Similar results were obtained in two recent studies 
in Japan (45). The Japan Eicosapentaenoic Acid Lipid 
Interventions Study (JELIS), a randomized trial of 18,645 
Japanese subjects that examined the effectiveness of 1.8 
g eicosapentaenoic acid per day plus a statin in reducing 
CHD rates, and the Japan Public Health Center-Based 
Study (JPHC), a 10-year prospective cohort study of 41,578 
middle-aged Japanese subjects that examined dietary 
intake of marine-derived n-3 fatty acids; both concluded 
that marine-derived n-3 fatty acids have protective effects 
against nonfatal coronary events.
Once or twice weekly consumption of fish (i.e., 30 g fish 
per day) is associated with reduced risk of cardiac death in 
Western countries. Increasing fish intake above this level 
is of little additional benefit. In contrast, Japanese men 
consume more than 100 g fish every day on average from 
early in life. Interestingly, omega-3 intakes in Japan are 
only one quarter of those among Eskimos, the population 
that gave origin to the omega-3 hypothesis.
Intriguing observations have been recently made in 
Alaska (46). Although some investigators continue to report 
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that Inuit consuming traditional diets have lower CHD rates, 
others are questioning this dogma. Recent evidence from 
the Genetics of Coronary Artery Disease in Alaska Natives 
(GOCADAN) Study indicates that carotid atherosclerosis is 
not only unrelated to omega-3 fatty acid intake but, surpris-
ingly, its prevalence is now greater than that in US white 
populations. At least part of the problem in Alaska appears 
to be not a lack of omega-3 but the introduction of mas-
sive amounts of shortenings and other saturated fats into 
their Westernizing diet. Saturated and monounsaturated 
fat intakes reported in the GOCADAN were approximately 
12 and 15% of energy, whereas in a similar age group in 
Japan, intakes were 8 and 9.4% of energy, respectively. 
This difference may be critical.
The Japanese experience, when contrasted to that of the 
Inuit and the Norwegians, suggests that the cardioprotec-
tive punch of the long-chain omega-3 fatty acids may be no 
match for diets high in fat, particularly saturated fat.
In general, current recommendations include regular 
ingestion of fish, 2-3 times/week.
Alcohol, red wine, polyphenols, resveratrol
Several observational and experimental studies have 
suggested a beneficial effect of mild/moderate alcohol drink-
ing on cardiovascular health and even total mortality (47). 
All clinical studies are concordant in that abstainers and 
heavy drinkers have higher mortality rates than individuals 
who drink moderately. 
For instance, Mukamal et al. (48) reported on the drinking 
habits of 245,207 adult Americans from 9 representative 
samples of US adults, from 1987 to 2000, as part of the an-
nual National Health Interview Survey; over 10,000 cardio-
vascular deaths occurred during that period. An inverse and 
significant association was found between light/moderate 
drinking and CVD mortality when compared to abstainers 
but not between consumption above recommended limits 
and CVD mortality. The effect was present in men, women, 
whites and non-whites and included coronary and stroke 
mortality; however, risk reduction tended to be stronger for 
CHD than for cerebrovascular disease. Also, Ronksley et al. 
(49) reported the results of a recent meta-analysis based 
on 84 studies regarding the association between alcohol 
consumption and CVD; they observed a 25% risk reduc-
tion in CVD mortality among moderate drinkers compared 
to non-drinkers; coronary disease incidence and coronary 
artery disease mortality showed similar reductions.
Alcohol increases HDL, which is protective against 
atherosclerosis, and polyphenols in red wine have many 
protective effects including vasodilation, anti-oxidation and 
anti-platelet effects. Non-cardiovascular diseases have 
also been reported to be favorably influenced by moderate 
drinking. However, these clinical studies are observational 
and no controlled investigation has ever been performed; 
uncertainties also remain regarding drinking frequency, 
quantity, binge drinking, and sources of alcohol, i.e., whether 
from wine, beer, whisky, or others. 
More recently, major interest has emerged regarding 
the possible beneficial effect of resveratrol - a polyphenol 
encountered in red wine, plants and fruits - on aging. So far 
the only intervention that effectively increases cell prolifera-
tion in culture and living organisms such as Saccharomyces 
cerevisae, fish and worms, is caloric restriction (50). Since 
resveratrol follows the same metabolic pathway as caloric 
restriction, including structural DNA preservation and P53 
reduction, the hypothesis was raised that it could prolong 
life. Indeed, in experiments with hypercholesterolemic mice, 
Baur et al. (51) demonstrated that resveratrol did just that. 
However, in healthy mice we (da Luz PL, Tanaka LY, Brum 
PC, Krieger JK, Dourado PM, Favarato D, et al., unpublished 
data) did not detect life extension by either resveratrol or 
red wine. Nevertheless, we did find preservation of vascular 
function, increased aerobic capacity, P53 reduction, and 
telomere length preservation, all of which suggest protec-
tive actions of both red wine and small doses of resveratrol 
on vascular function. 
Both these experimental and clinical observation studies 
show a potential benefit of moderate alcohol consumption, 
especially red wine. However, direct controlled studies on 
men are still locking.
Exercise 
Regular exercise reduces cardiovascular events (52) 
through a number of physiological mechanisms. The most 
striking metabolic effect of exercise is to reduce plasma TG; 
but exercise also reduces insulin resistance and therefore 
contributes to diabetes control; regular exercise decreases 
blood pressure and increases HDL but has no effect on 
LDL. It improves mood, body weight, and inflammatory and 
hemostatic variables. Physical training improves exercise 
capacity, increases collaterals in CAD patients and improves 
endothelial function. 
Following coronary artery bypass grafting (CABG) and 
percutaneous coronary intervention (PCI), it improves VO2 
as well as quality of life. Hence, it is now considered to be 
part of recovery programs following these interventions. In 
the long term it reduces sudden coronary death; however, 
sudden death is more frequent during intense exercise than 
during moderate exercise. In our group, Casella-Filho et al. 
(53) assessed the effects of a 3-month supervised physical 
training program in 30 patients with metabolic syndrome in-
cluding low HDL (≤40 mg/dL) and noted that brachial arterial 
flow-mediated dilation improved significantly after exercise 
although total HDL and LDL remained at the same baseline 
values. Also, HDL from trained individuals significantly in-
creased LDL resistance to oxidation. They interpreted the 
data as evidence that exercise can functionally improve 
HDL even if its total value does not change, probably by 
interference with its sub-fractions. Thus, even short periods 
of exercise can substantially ameliorate endothelial function 
while increasing resistance to LDL oxidation. 
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The molecular mechanisms underlying the beneficial 
effects of exercise were examined by Werner et al. (54) in 
wild mice and in endothelial nitric oxide synthase (eNOS)- 
and telomerase reverse transcriptase (TERT)-deficient 
mice subjected to 21 days of voluntary running. In normal 
mice, short-term voluntary running up-regulated cardiac 
telomerase activity, reduced the expression of proapoptotic 
mediators such as cell-cycle-checkpoint kinase 2, p16 
and p53, compared to sedentary controls. Running also 
prevented doxorubicin-induced apoptotic cell death. In 
eNOS and TERT knockout mice, running had no effect, thus 
indicating the pivotal role of these enzymes as mediators of 
the effects of exercise. Further characterization permitted 
these investigators to establish that these salutary effects 
of running were also mediated by insulin growth factor-1. 
These effects persisted for at least 6 months. This is an 
important, novel contribution to our understanding of the 
mechanisms underlying the benefits of exercise. 
These lines of evidence justify why cardiologists recom-
mend regular exercise programs for CVD prevention and 
treatment. Tolerance to exercise through stress testing, how-
ever, should be assessed before entering such programs. 
Performing exercise within safe ranges of submaximum 
tolerance rather than at extenuating levels is a salutary 
practice, since excessive strain may induce sudden death 
in people with CAD. It is consensual among cardiologists 
that the optimal frequency of moderate exercise is 30 min/
day, 4-5 times/week at least, on a long-term basis.
Smoking
A comparison of mortality by lung cancer in people who 
never smoked, those who quit smoking at age 30 or age 
50, and those who continued to smoke is very revealing 
(1). People who never smoked had almost no mortality by 
age 75 due to cancer; people who continued to smoke, 
had a death rate about 12 times higher; quitting at age 30 
was better than at 50, but in both cases it was significantly 
better than continuing to smoke. 
In heart disease, many studies have shown the benefits 
of not smoking or quitting smoking. Iestra et al. (55), review-
ing studies on the effects of smoking cessation, estimated 
at 35% the reduction in mortality among patients with CAD 
and at 50% in the general population. This greater benefit 
in the general population is largely attributable to cancer 
prevention. Although quitting smoking has been a formal 
cardiologist recommendation for many years, its implemen-
tation remains a considerable challenge.
Obesity and diabetes
Obesity is one of the most prevalent risk factors, not 
only in Brazil but also all over the world. Even children and 
adolescents are suffering, which is a unique phenomenon 
in the history of humanity. A BMI above 30 is considered 
obesity while the normal index ranges from 23 to 25. Causes 
of obesity are essentially two: 1) excessive caloric ingestion 
mainly through foods rich in fats and carbohydrates and 2) 
lack of exercise. Both situations are frequently associated 
with psychological factors including anxiety, stress and 
depression.
Obesity is frequently associated with diabetes and 
metabolic syndrome, which in turn predispose to CAD. As 
shown above (25), obesity reduces life expectancy and 
greatly impairs quality of life.
In principle, obesity can be avoided or treated. Several 
measures are required for this purpose: a diet with no ex-
cessive calories, principally restricting saturated fats and 
carbohydrates; regular exercise; medications to control 
excessive anger, and, most recently, bariatric surgery. But 
all require major changes in lifestyle. Cognitive behavioral 
therapy (56) is of particular value in this respect, as well 
as counseling by a nutritionist. Unfortunately, the long-term 
efficacy of weight reducing programs is disappointing, as 
shown by the Diabetes Prevention Program Research Group 
(57); although patients respond well initially, they regain 
weight over the next 1-2 years. Thus, we emphasize the 
need for patients to avoid gaining weight since programs to 
lose weight require considerable determination and personal 
“sacrifices” and hence are especially hard to implement on 
a long-term basis. 
Multiple interventions
 
Some population studies are particularly relevant regard-
ing human longevity (58). Japanese in Okinawa, Californians 
in Loma Linda and Italians in Sardinia are known for their 
exceptionally long survival rate and healthy behavior under 
normal environmental conditions. Independent of their ori-
gins, five traits are common to all these communities: they 
do not smoke, they prioritize the family, maintain constant 
physical activity, have an active social life, and eat fruits, 
vegetables and whole grains. Use of medications is virtually 
unheard of. In Brazil, Veranópolis, in Rio Grande do Sul, is 
also known for exceptional longevity (59). The life habits of 
its inhabitants are quite similar to those of the communities 
cited above; one common characteristic with the Sardinians 
is regular wine drinking. No genetic traits seem to explain 
these findings. These “nature’s experiments” demonstrate 
how important a healthy lifestyle is for preservation of a long, 
active life. Figure 6 illustrate these common features. 
Fraser and Shavlik (60) analyzed the effects of appro-
priate diet, non-smoking and exercise among Adventists 
in California compared to general Californian population; 
they observed a gain in life expectancy at 30 years, of 7.28 
years in men and 4.42 in women who followed the recom-
mended healthy habits.
Ornish et al. (61) published a remarkable study of 
people who were subjected to intensive lifestyle changes, 
including diet, exercise, social, religious, and psychological 
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counseling. Forty-eight patients were randomly assigned 
to the intensive regimen or to usual care, and subjected to 
coronary angiography for lesion quantification. After five 
years, lesion regression was observed in the treatment 
group, while progression occurred among controls. Admit-
tedly, such intense regimen is difficult to apply to most 
people; nevertheless, the study does prove the point that 
a proper lifestyle can modify the natural history of athero-
sclerotic plaques. 
Knoops et al. (62) reported on pooled results of the 
HALE, SENECA and FINE studies (Figure 7). The effects 
of diet, exercise, not smoking, and moderate alcohol con-
sumption on event rate were analyzed in 1507 elderly men 
and 832 women followed for 12 years. A proper diet and 
moderate alcohol consumption both reduced risk by 25%; 
regular exercise and not smoking, both reduced risk by 
40%; most impressive, individuals who observed all four 
habits, had a 65% risk reduction. It is noteworthy that this 
figure by far exceeds the best results obtained with drug 
therapy in all secondary prevention trials! 
Taken together, these studies highlight the major impact 
of very simple measures on general health.
Psychological and environmental factors 
Psychological, social and environmental factors have 
long been recognized as capable of influencing the devel-
opment and clinical evolution of atherosclerosis. In-depth 
discussion of these many factors can be found elsewhere 
(56); here we only intend to illustrate how some of them 
have an impact on clinical settings. In addition, their impor-
tance derives from the fact that they are quite frequent and 
in many instances their clinical manifestations resemble 
organic diseases, such as palpitations and chest discom-
fort, thus leading to erroneous diagnoses. CAD has been 
related to five specific psychological factors (56): anxiety, 
depression, character traits and personality, social isola-
tion, and chronic life stress. Work conditions, family (marital 
status, widowhood, parent/child relationships) and chronic 
illnesses are among the most common conditions in which 
chronic stress may occur. For instance, work stress, a form 
of chronic life stress, may affect CVD by two mechanisms: 
SARDENES
Drink red wine (moderatly)
Share work with spouse
Eat pecorin cheese
(and other omega-3 rich foods)
ADVENTISTS
Eat nuts and beans
Respect saturday
Have faith
OKINAWANS
Maintain all life friends
Eat small portions
Find a meaning for life
A LL
Do not smoke
Prioritize famíly
Physically active
Maintain social life
Eat fruits, legumes and 
Integral grains
Figure 6. Common lifestyle features among populations who live longest. Reproduced with permission from Ref. 58.
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direct stimulation of neuroendocrine responses to stressors 
or indirectly by unhealthy behaviors: diet, smoking, lack of 
exercise, and excessive drinking (Figure 8). The autonomic 
nervous system is a major axis of neuroendocrine stress 
responses and work stress leads to disregulation of the 
hypothalamic-pituitary-adrenal axis. Indeed, Chandola et al. 
(63) assessed the influence of work stress on behavioral and 
physiological indices regarding CHD incidence in 10,308 civil 
servants of the Whitehall II Study over a 12-year follow-up. 
They observed that work stress was associated with poor 
health behavior (eating less fruits and vegetables), less 
physical activity, metabolic syndrome, lower heart rate vari-
ability, and elevated morning cortisol, especially in younger 
participants (37-49 years). Greater reports of work stress 
were associated with higher risk of CVD, i.e., fatal events, 
MI and definite angina. The authors calculated that about 
32% of the effect of work stress on CHD can be explained 
by health behaviors (especially low physical activity and 
a poor diet) and the metabolic syndrome. Importantly, in 
the INTERHEART Study (64) that analyzed about 24,767 
patients with first AMI in 52 countries, noted that permanent 
stress at the work place was associated with more than a 
2-fold increase in the risk of AMI, compared to subjects 
who reported no such stress. 
Hamer et al. (65) investigated the extent to which 
behavioral and traditional risk factors accounted for the 
association between psychological distress and cardiovas-
cular events. In a prospective study of 6576 healthy adult 
men and women, psychological distress was measured by 
the General Health Questionnaire and the subjects were 
followed for 7.2 years. Outcome events were non-fatal 
AMI, bypass surgery, angioplasty, stroke, heart failure, and 
cardiac mortality. Alcohol intake, physical activity, cigarette 
smoking, hypertension, and CRP were independently 
associated with psychological distress. The risk of CVD 
increased in proportion to the presence of psychological 
distress in gender- and age-adjusted models. Behavioral 
factors accounted for approximately 60% of variance, while 
traditional risk factors (CRP, 5.5%, and hypertension, 13%) 
accounted for modest amounts. The authors concluded 
that “the association between psychological distress and 
CAD is largely explained by behavioral processes”. Hence, 
health behavior change should be the main target for 
treatment when focusing on psychological distress. Lower 
occupational status and low job control have also been 
linked to BMI and central obesity, two known risk factors 
for CAD (66). 
Strategies to deal with psychological stress include 
several interventions. Exercise, which is commonly rec-
ommended to prevent CAD, also has favorable effects on 
depression. The impact of psychosocial interventions added 
to cardiac rehabilitation programs was assessed by Linden 
et al. (67) in a meta-analysis of 23 randomized trials; during 
a 2-year follow-up, psychosocial intervention had a favorable 
Figure 7. Comparison of four healthy habits among elderly people. Note that those who adopted all four healthy behaviors had a risk 
reduction of about 65%, which is greater than that obtained with any drug therapy. Reproduced with permission from Ref. 62. 
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impact on mortality and recurrent infarction. However, they 
(67) observed that such positive effect was dependent on 
the efficacy of the psychological intervention; thus, when 
stress was not reduced, the intervention had no effect. In 
fact, absence of a response seemed to identify a subgroup 
of individuals at particularly high risk. Other investigations 
suggested mixed results.
Psychopharmacologic therapies have also been advo-
cated. The SADHART Trial (67) demonstrated that sertra-
line, which is an effective antidepressant drug, can be safely 
prescribed to treat depression in patients with known CAD; 
but the study was not powered to analyze events. On the 
other hand, tricyclic anti-depressants increased the risk of 
subsequent MI, as shown by Cohen et al. (68). 
More recently, behavioral cognitive therapy has been 
incorporated into clinical practice as a valuable tool for 
patients with established coronary disease or multiple risk 
factors who need lifestyle changes for event and recurrence 
prevention, or better adherence to treatment. It should be 
viewed as adjunct therapeutic intervention; together with 
drug therapy it may increase the effectiveness of reha-
bilitation programs and long-term adherence to preventive 
measures.
As stated by Rozanski et al. (56), the “emerging field of 
behavioral cardiology” is a relatively new area of interest 
for research and practice. From the patients’ perspectives 
some aspects need clarification: it is not uncommon that 
patients do not recognize or do not accept that psychological 
factors may produce a significant impact on their health; 
as a consequence they do not spontaneously mention 
them to their physicians; they may consider, for instance, 
that marital problems are intimate problems and should 
not be mentioned in a regular consultation. Furthermore, 
lay persons frequently consider that they can handle such 
Figure 8. Schematic representation of the relationship between mental stress, atherosclerosis and clinical events. Chronic emotional 
stress may be induced by several life circumstances. They can cause hormonal activation on the one hand and, on the other, induce 
behaviors that lead to atherosclerosis development and progression. ANS = autonomic nervous system. ROS = reactive oxygen spe-
cies.
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problems on their own, when in fact professional counsel-
ing can be necessary. Finally, acceptance of psychological 
counseling is still hampered by all sorts of misconceptions. 
While requests by the attending physician of a second 
opinion from another specialist, let’s say, a pneumologist, 
is readily accepted by the patient, the same request for a 
psychologist’s opinion is questioned, ignored or flatly dis-
missed. From a doctor’s perspective, more awareness of 
such problems is needed; and then, appropriate inquiries 
should be carried out to identify them. Without intruding 
into personal issues, that a patient might want to keep to 
himself, some general questions can be posed, such as: 
“Do you feel you are going through a particularly difficult 
time in your life?“. The answer can offer a suggestion as 
to whether emotional stress is part of a given situation. Of 
course, in this scenario mutual confidence between doctor 
and patient is of paramount significance. 
Since Freud’s incursions into the unconscious, it be-
came clear how fundamental it is to understand the human 
soul. Although the new technological era has unraveled so 
many biological phenomena, human behavior remains a 
Pandora’s box. Behavioral cognitive therapy is a new tool 
that can help not only strictly psychological dysfunction, 
but also patients whose poor behavior leads to unhealthy 
habits and hence, to atherosclerosis.
The five most important factors
 
As shown above, several factors contribute to a healthy 
lifestyle. Based on the 16-year follow-up of the Health 
Professional Study, Chiuve et al. (69) identified five items 
associated with lower cardiac risk: non-smoking, BMI ≤25, 
regular exercise (30 min/day), healthy diet (fruits, veg-
etables, low saturated fat) and 5-30 g alcohol/day. For each 
of the items followed there was a corresponding decrease 
in risk and this was true regardless of medication use, and 
was applicable to both men and women. Similarly, strokes 
were also significantly reduced among 43,685 men and 
712,423 women who followed the same five recommenda-
tions (70). Note that these five factors are not particularly 
difficult to follow; however, experience shows that it is much 
easier to adhere to them in a preventive fashion rather than 
adopting them when atherosclerosis is already present and 
unhealthy behavior needs correction.
Policies required
Implementation of a healthy lifestyle is notoriously 
difficult, both at the individual and population levels. For 
individuals, the long-term dangerous consequences of a 
poor lifestyle should be clearly stated by doctors, especially 
because many risk factors are silent, and therefore the 
need for modifying habits may not be readily understood 
by patients. Secondly, global care is mandatory, includ-
ing nutritional and psychological counseling. Regarding 
population-based programs, the contribution of different 
social components is fundamental. Namely, a) schools 
must be a focus because habits are better assimilated at 
an early age; b) government can influence society through 
regulatory policies; c) the media can help implement 
healthy lifestyles since its messages permeate all levels of 
societies and are extremely powerful; d) parents/family play 
an important role since habits acquired within the family are 
strongly respected; the family is the most important nucleus 
where behavior is acquired because it is based mainly 
on examples; e) medical societies have the obligation to 
transmit scientific knowledge to the society in simple, clear 
language. They must “translate” discoveries into practical 
lessons that will become actions. 
Although difficult, this is a task that health professionals 
and society alike must tackle.
Conclusions
Drugs are powerful, indispensable weapons against 
CVD. However, because they are expensive, they have 
side effects and are only partially effective, they are not 
sufficient. The issue of costs is a major one since CVD hits 
poor countries as well as rich ones, and individual patients 
cannot cope with long treatment expenses. In addition, 
even rich countries are suffering with the escalating costs 
of medical care. 
In contrast, a healthy lifestyle is inexpensive, safe and 
effective. However, it is not simple to implement. It requires 
changes in traditional habits, including diet, exercise and 
smoking. It also demands discipline because it interferes 
with some practices that are deemed pleasant. Furthermore, 
determination is needed since a healthy lifestyle is predi-
cated upon long-term behavior. In addition to responsible 
medical care, psychological and nutritional counseling, 
social and family support are also needed to implement 
behavior modification. Experiences so far demonstrate how 
hard it is to obtain such changes; old habits are difficult to 
modify. Application to large communities is another obstacle, 
but a few experiences prove that it is possible. Admittedly, 
these population policies represent a major challenge for 
the medical community and society as well. However, in 
view of the predicted CVD epidemics ahead of us, this task 
will have to be faced.
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